Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...

Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumors HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) --...

Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsHOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) --...

INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT HOUSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...